New cholesterol combo drug shows promise in early trial

NCT ID NCT06742853

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested a new drug called AZD0780 in 81 healthy adults with high cholesterol. Participants received AZD0780 alongside other cholesterol-lowering medicines like ezetimibe, rosuvastatin, or bempedoic acid. The goal was to see how well the combination lowers LDL (bad) cholesterol and whether it is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD0780 (a drug to lower cholesterol) combined with ezetimibe, rosuvastatin, or bempedoic acid
What this could lead to: If successful, this could point toward a new combination treatment to lower high cholesterol more effectively.
What could go wrong: This is an early Phase 1 trial with only 81 people, so results may not apply to everyone. The drug may cause side effects or not work as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias Hypercholesterolemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIA

Contacts and locations

Locations

Research Site

Glendale, California, 91206, United States
Research Site

Brooklyn, Maryland, 21225, United States
Research Site

Harrow, HA1 3UJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.